DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 195
- Registration Number
- NCT02764541
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Dana-Farber at St. Elizabeth's Medical Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors
- Conditions
- Insomnia
- Interventions
- Behavioral: CBTI-CS via TelehealthBehavioral: CBTI-CSBehavioral: Sleep Hygiene
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT02756390
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy
- Conditions
- Breast Cancer
- Interventions
- Procedure: Axillary Lymph Node Sampling Clip
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT02752009
Hereditary Risk Factors for Thyroid Cancer
- Conditions
- Thyroid Cancer
- Interventions
- Genetic: •Referral to Genetic Counselor, if indicated
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2025-05-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 250
- Registration Number
- NCT02747888
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Advanced Non-Clear Cell Kidney Cancer
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 65
- Registration Number
- NCT02724878
- Locations
- 🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2021-07-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT02706249
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 127
- Registration Number
- NCT02698891
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dana-Farber/New Hampshire Oncology-Hematology, Londonderry, New Hampshire, United States
🇺🇸Dana-Farber at Milford Regional Cancer Center, Milford, Massachusetts, United States
MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT02689401
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
- First Posted Date
- 2016-02-09
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 33
- Registration Number
- NCT02677324
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
- Conditions
- Recurrent, Refractory, or High Risk LeukemiasMatched Targeted Therapy
- Interventions
- Genetic: Leukemia Profiling
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 338
- Registration Number
- NCT02670525
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States